scholarly journals Is It Safe to Proceed with Thrombolytic Therapy for Acute Ischemic Stroke in a Patient with Cardiac Myxoma?

2013 ◽  
Vol 69 (2) ◽  
pp. 67-67 ◽  
Author(s):  
Nitin K. Sethi
Keyword(s):  
Ischemic Stroke ◽  
Thrombolytic Therapy ◽  
Acute Ischemic Stroke ◽  
Cardiac Myxoma

scholarly journals Outcomes of Thrombolytic Therapy for Acute Ischemic Stroke in Chinese Patients

Stroke ◽  
2010 ◽  
Vol 41 (5) ◽  
pp. 885-890 ◽  
Author(s):  
A-Ching Chao ◽  
Hung-Yi Hsu ◽  
Chih-Ping Chung ◽  
Chung-Hsiang Liu ◽  
Chih-Hung Chen ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Thrombolytic Therapy ◽  
Acute Ischemic Stroke ◽  
Chinese Patients

scholarly journals A Description of Canadian and United States Physician Reimbursement for Thrombolytic Therapy Administration in Acute Ischemic Stroke

Stroke ◽  
2005 ◽  
Vol 36 (3) ◽  
pp. 682-687 ◽  
Author(s):  
Dawn Kleindorfer ◽  
Michael D. Hill ◽  
Daniel Woo ◽  
Thomas Tomsick ◽  
Arthur Pancioli ◽  
...  
Keyword(s):  
United States ◽  
Ischemic Stroke ◽  
Thrombolytic Therapy ◽  
Acute Ischemic Stroke ◽  
Physician Reimbursement

Comparative Analysis on Low- and Standard-Dose Regimes of Alteplase Thrombolytic Therapy for Acute Ischemic Stroke: Efficacy and Safety

2017 ◽  
Vol 79 (1-2) ◽  
pp. 68-73 ◽  
Author(s):  
Guangjian Zhao ◽  
Tingfen Huang ◽  
Mei Zheng ◽  
Yansen Cui ◽  
Yunyong Liu ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Thrombolytic Therapy ◽  
Acute Ischemic Stroke ◽  
Dose Group ◽  
Low Dose ◽  
Standard Dose ◽  
Efficacy And Safety ◽  
Significant Difference ◽  
Symptomatic Intracranial Hemorrhage ◽  
Intravenous Alteplase

Objective: This study analyzed the efficacy and safety of low-dose and standard-dose alteplase intravenous thrombolytic therapy for acute ischemic stroke (AIS). Methods: Patients with AIS who underwent intravenous alteplase thrombolysis from July 2012 to December 2016 were retrospectively analyzed and correspondingly divided into low-dose (0.6–0.89 mg/kg) group and standard-dose group (0.9 mg/kg) according to alteplase dosage. The clinical outcome was evaluated by modified Rankin Scale (mRS) at 90 days after onset. The safety index was the mortality at 90 days after onset and the incidence of symptomatic intracranial hemorrhage (SICH) within 7 days. Results: A total of 1,486 patients were included (1,115 cases in low-dose group and 371 cases in standard-dose group). There were no significant differences in baseline data between the 2 groups. As mRS, good outcome rate as well as mortality rate in both groups had no significant difference (36.1 vs. 37.6%; χ2 = 10.882, p = 0.890; 5.5 vs. 7.3%; χ2 = 2.163, p = 0.076), but the incidence of SICH in low-dose group was significantly lower than that of the standard-dose group (2.2 vs. 5.9%; χ2 = 3.157, p = 0.001). Conclusion: The efficacy of low-dose alteplase intravenous thrombolytic therapy for AIS was equivalent to the standard-dose regimen but with higher safety.

Drip and Ship Thrombolytic Therapy for Acute Ischemic Stroke

Stroke ◽  
2015 ◽  
Vol 46 (3) ◽  
pp. 732-739 ◽  
Author(s):  
Kevin N. Sheth ◽  
Eric E. Smith ◽  
Maria V. Grau-Sepulveda ◽  
Dawn Kleindorfer ◽  
Gregg C. Fonarow ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Thrombolytic Therapy ◽  
Acute Ischemic Stroke

Drip-and-ship thrombolytic therapy for acute ischemic stroke

2017 ◽  
Vol 381 ◽  
pp. 624
Author(s):  
S. Mizuno ◽  
I.D. Ichiro Deguchi ◽  
S. Kohyama ◽  
N. Tanahashi ◽  
M. Takao
Keyword(s):  
Ischemic Stroke ◽  
Thrombolytic Therapy ◽  
Acute Ischemic Stroke
Sign in / Sign up

Export Citation Format

Share Document